Company intelligence / Profile preview

Hehuang Pharmaceutical

Shanghai, Shanghai, Chinacn.kompass.com ↗

Ownership: Private
Development stage: Commercial

Overview

Hehuang Pharmaceutical is a leading traditional Chinese medicine company with a focus on cardiovascular and cerebrovascular diseases. Its flagship product, Shexiang Baoxin Pill, is widely used for myocardial infarction treatment and has achieved significant sales growth. The company also produces Danning tablets, which have been registered internationally in Canada. In 2023, the company's revenue was 2.7 billion yuan with net profit of 660 million yuan; from January to October 2024 revenue reached 2.469 billion yuan with net profit of 625 million yuan.

Therapeutic areas: GastroenterologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Major partnership/joint venture history with Shanghai Pharmaceuticals since founding as a JV in ~2001.

Beyond the preview

Go deeper on Hehuang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hehuang Pharmaceutical.

Explore the full profile